shields pharmacy semaglutide reviews Compound Review Shields Pharmacy | Nationwide Compounding

In contrast, the rate of retained gastric contents in GLP-1RA users undergoing both oesophago-gastroduodenoscopy and colonoscopy was significantly reduced

The FDA expanded semaglutide's (Wegovy) use to reduce the risk of cardiovascular death, heart attack, or stroke in adults with cardiovascular disease and overweight or obesity, based on a cardiovascular outcomes trial in which it reduced major adverse cardiovascular events by 20% compared with placebo

Conversely, others experience nausea, early satiety, or gastrointestinal discomfort that can temporarily worsen mood or reduce social engagement

However I think any medication should be very sparingly used and only if absolutely needed

Clinical trials show modest additional weight loss (25%) when naltrexone is added to semaglutide, but the benefit varies significantly between individuals